DermTech International said this week that it has added three members to its commercialization team: Art Wampole will lead the company's sales efforts, Annie Bell its marketing strategy, and Mildred Romero its reimbursement implementation.
Wampole was previously vice president of sales at Dermpath Diagnostics, a division of Ameripath, now part of Quest Diagnostics.
Bell held senior management positions in sales and marketing for Ameripath, and was the general manager of Dermpath Diagnostics.
Romero has held senior management positions and led reimbursement development at several diagnostics companies including DexCom and Pathway Genomics.
Diomics said this week that it has appointed Thomas Kindt as CSO.
Kindt was previously director of intramural research at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. He also served as chief of the laboratory of immunogenetics at NIAID, and spent a year as a visiting scientist in the Analytical Immunohistochmistry Laboratory at the Institute Pasteur. Prior to this he was with Rockefeller University and the City of Hope National Center in Duarte, Calif.
In his new role as CSO, Kindt "will lead the discovery and enhanced product development efforts of the company," CEO John Steel said in a statement. "The application of X-Swab as an effective tool for low template DNA recovery for increasing yield during PCR remains a research priority for the company. Dr. Kindt's contribution to this mission will be invaluable."
Diomics' technology was recently highlighted in the journal Forensic Science International: Genetics, covered this week in PCR Insider.